Staff Profile
Dr Jack Goddard
Research Associate
- Email: jack.goddard@ncl.ac.uk
- Address: Wolfson Childhood Cancer Research Centre,
Newcastle University Centre for Cancer,
Translational & Clinical Research Institute,
Level 6 Herschel Building,
Brewery Lane,
Newcastle upon Tyne,
NE1 7RU
Positions:
Research Associate - Paediatric Brain Tumour Group, Newcastle University (2023 to present)
Education:
PhD, Molecular Paediatric Oncology - Newcastle University (2023)
MRes, Biomedical Science with specialisation in Molecular Genetics - University of Glasgow (2018)
BSc (Hons), Genetics - University of Glasgow (2017)
Honours and Awards:
Faculty of Medical Sciences Doctoral Thesis Prize - Newcastle University
Poster award for 'scientific excellence in the field of paediatric neuro-oncology' - International Symposium on Pediatric Neuro-Oncology (ISPNO 2022)
Newcastle University Doctoral College Enhancement Fund Award
BACR Student Travel Award
Memberships:
British Association for Cancer Research (BACR)
European Association for Cancer Research (EACR)
Research focus:
Molecular pathology of medulloblastoma
Research theme:
Precision Medicine, Genomics and Informatics
Teaching:
Biochemistry (BGM1002) - Seminar leader
Supervision:
BSc Biomedical Sciences project supervisor
MRes Cancer Studies project supervisor
-
Articles
- Keeling C, Davies S, Goddard J, Ramaswamy V, Schwalbe EC, Bailey S, Hicks D, Clifford SC. The clinical significance of sub-total surgical resection in childhood medulloblastoma: a multi-cohort analysis of 1100 patients. eClinicalMedicine 2024, 69, 102469.
- Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, Garcia-Ariza M, Navajas A, Masliah-Planchon J, Bourdeaut F, Dufour C, Ayrault O, Goschzik T, Pietsch T, Sill M, Pfister SM, Rutkowski S, Richardson S, Hill RM, Williamson D, Bailey S, Schwalbe EC, Clifford SC, Hicks D. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. Acta Neuropathologica 2023, 145, 651–666.
- Williamson D, Schwalbe EC, Hicks D, Aldinger KA, Lindsey JC, Crosier S, Richardson S, Goddard J, Hill RM, Castle J, Grabovska Y, Hacking J, Pizer B, Wharton SB, Jacques TS, Joshi A, Bailey S, Clifford SC. Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development. Cell Reports 2022, 40(5), 111162.